[ad_1]
A council building in Leicestershire has been identified as a mass vaccination site, and the UK is preparing to implement widespread coronavirus attacks if security regulators give the go-ahead.
Charnwood Borough Council has told Sky News that an area of its offices will be turned over to Defense Ministry teams in mid-December “for at least nine months.”
Council leader Jonathan Morgan said the building would be used as a COVID-19 vaccination site for “about 185,000 people in the area.”
He said: “We are very excited to be at the forefront of this, and as soon as a vaccine is ready, this site is ready to go.”
Charnwood City Council Leader Jonathan Morgan said the site will be used by about 185,000 people in the area.
Charnwood Borough Council covers the city of Loughborough, including the university.
It occurs when the Derby City Council confirmed that talks were underway to use Derby Arena as a temporary facility to help administer vaccines.
Health Secretary Matt Hancock told Sky News that he hopes a mass vaccination program for COVID-19 to be launched “in a matter of weeks”.
A vaccine has not yet received official approval, but it has been found that both treatments led by EE. UU. They have superior efficacy to 90% to protect people coronavirus after large-scale phase three trials.
The manufacturers, Pfizer and Moderna, have reported overall efficiencies of 95% and 94.5%, respectively.
Use the Chrome browser for a more accessible video player
UK ‘weeks away’ from vaccine launch
Pfizer has now said that it was asking US regulators to allow emergency use of the vaccine, which it has developed with its German partner BioNTech. The UK has ordered 40 million doses, enough to treat 20 million people.
Moderna also expects to apply for an emergency authorization from the United States within a few weeks. The UK has ordered five million doses of the jab for the spring of next year.
Meanwhile, the COVID-19 vaccine developed by the University of Oxford produces a strong immune response in older adults, data from early trials have shown.
The results from phase one and phase two suggest that one of the groups most at risk of death or serious illness from COVID-19 could develop immunity, according to data published in the medical journal The Lancet.
The UK government has ordered more than 100 million doses of the Oxford vaccine and expects the final results to be just as promising as Pfizer and Moderna.
[ad_2]
